全文获取类型
收费全文 | 22014篇 |
免费 | 1693篇 |
国内免费 | 611篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 289篇 |
妇产科学 | 188篇 |
基础医学 | 1484篇 |
口腔科学 | 175篇 |
临床医学 | 1909篇 |
内科学 | 5080篇 |
皮肤病学 | 308篇 |
神经病学 | 1122篇 |
特种医学 | 297篇 |
外国民族医学 | 1篇 |
外科学 | 2441篇 |
综合类 | 1632篇 |
现状与发展 | 2篇 |
预防医学 | 659篇 |
眼科学 | 226篇 |
药学 | 5366篇 |
10篇 | |
中国医学 | 311篇 |
肿瘤学 | 2713篇 |
出版年
2024年 | 29篇 |
2023年 | 488篇 |
2022年 | 637篇 |
2021年 | 1060篇 |
2020年 | 1000篇 |
2019年 | 892篇 |
2018年 | 829篇 |
2017年 | 895篇 |
2016年 | 817篇 |
2015年 | 915篇 |
2014年 | 1243篇 |
2013年 | 2471篇 |
2012年 | 1155篇 |
2011年 | 1349篇 |
2010年 | 1011篇 |
2009年 | 1024篇 |
2008年 | 983篇 |
2007年 | 933篇 |
2006年 | 874篇 |
2005年 | 681篇 |
2004年 | 558篇 |
2003年 | 545篇 |
2002年 | 495篇 |
2001年 | 388篇 |
2000年 | 326篇 |
1999年 | 273篇 |
1998年 | 267篇 |
1997年 | 256篇 |
1996年 | 199篇 |
1995年 | 187篇 |
1994年 | 150篇 |
1993年 | 152篇 |
1992年 | 118篇 |
1991年 | 105篇 |
1990年 | 96篇 |
1989年 | 92篇 |
1988年 | 76篇 |
1987年 | 93篇 |
1986年 | 59篇 |
1985年 | 86篇 |
1984年 | 77篇 |
1983年 | 52篇 |
1982年 | 78篇 |
1981年 | 53篇 |
1980年 | 54篇 |
1979年 | 46篇 |
1978年 | 45篇 |
1977年 | 28篇 |
1976年 | 27篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
Activated prothrombin complex concentrate (FEIBA® ) treatment during surgery in patients with inhibitors to FVIII/IX 总被引:1,自引:0,他引:1
Non-activated and activated prothrombin complex concentrates (PCC/aPCC) have been used successfully to treat bleeds in haemophilia patients with inhibitors, but most physicians do not consider these products as effective as factor VIII/IX (FVIII/IX) concentrates in non-inhibitor patients. Thus, surgical procedures in inhibitor patients have been performed reluctantly. We have performed 14 minor and five major surgical and invasive diagnostic procedures in eight patients with congenital haemophilia A and inhibitors and in two patients with acquired haemophilia. When a loading dose of 100 U kg-1 of FEIBA was given followed by 200 U kg-1 day-1 in three divided doses every 8 h for 3 days, and then, when the daily dose was tapered to 100-150 U kg-1, no severe or unexpected bleeding complications were observed. However, one adverse event was observed. A 69-year-old man who suffered a myocardial infarction the third postoperative day following sigmoidectomy was managed safely with opiate analgesia, nitrates and diuretics, and the continued use of FEIBA(R). 相似文献
103.
肝纤维化组织中MMP1、TIMP1的表达及其临床意义 总被引:2,自引:1,他引:1
目的 :检测肝纤维化组织中基质金属蛋白酶 1 (MMP1 )、基质金属蛋白酶组织抑制因子 1 (TIMP1 )的表达 ,为肝纤维化的诊治提供重要的分子生物学指标。 方法 :采用链霉菌抗生物蛋白 -过氧化酶联接法 (S- P法 )检测70例肝纤维化组织中 MMP1 、TIMP1 的表达。结果:(1) TIMP1 蛋白阳性表达随肝纤维化程度的加重而增强 ,并且呈正相关关系 (r=0 .92 74 ,P <0 .0 1)。 (2 ) MMP1 蛋白阳性表达随肝纤维化程度的加重无明显变化 ,无相关关系(r =0 .2 181,P >0 .0 5 )。 结论:TIMP1 与肝纤维化的发生、发展密切相关 ,随纤维化发生、发展阳性表达增强。从分子水平对肝纤维化、肝硬化病变进行评估 ,为早期诊治肝纤维化和判断预后提供依据。 相似文献
104.
105.
Giovanni Vanni Frajese Flavio Pozzi Gaetano Frajese 《Clinical Interventions in Aging》2006,1(4):439-449
Prevalence and severity of erectile dysfunction (ED) increase with aging and are often associated with illnesses, like diabetes mellitus, heart disease, and hypertension, pathologically characterized by endothelial dysfunction and whose prevalence increases with age. The assumption that ED is mainly a neurovascular disease is supported by the evidence that specific phosphodiesterase type 5 (PDE5) inhibition produces an efficient erection in a wide range of ages and conditions. The availability of specific PDE5 inhibitors has enabled the development of effective treatment strategies, in this contest, tadalafil may be considered as the least “typical” PDE5 inhibitor. In clinical trials, tadalafil significantly enhanced, in patients of different ages, all efficacy outcomes across disease etiologies and severities. With an effectiveness lasting up to 36h, tadalafil allows patients to choose when to have sexual activities without the need to time it, showing positive feedback in terms of quality of life related to the treatment. Headache and dyspepsia were the most frequent side-effects of tadalafil, followed by back pain, nasal congestion, myalgia, and flushing, but the impact that long time action could have on effectiveness and safety is not yet entirely defined. The aim of this article is to critically review the available evidence from the tadalafil clinical research program and give the physician a rational approach for intervention in the treatment of ED and related diseases. 相似文献
106.
全植入式药泵行肝血管灌注治疗晚期肝癌 总被引:6,自引:2,他引:4
对24例不能切除的晚期肝癌采用完全植入式药泵行肝动脉和门静脉双灌注化疗。结果:部分缓解(PR)15例(62.5%),稳定(S)8例(33.3%),进展(P)1例。平均生存期为9.17月,半年生存率为66.7%,1年为25%。在AFP>400μg/L的10例中,5例下降。 相似文献
107.
血卟啉衍生物(YHpD)合并照光对S180瘤细胞摄取~(86)Rb,瘤细胞的钠泵活性及糖酵解具有明显的抑制作用,且抑制程度随YHpD剂量的增大而增强。瘤细胞的总ATP酶和(Na-K)-ATP酶活性对YHpD的光动力效应也较敏感.YHpD对Mg—ATP酶活性有轻度抑制作用。YHpD并用哇巴因,对瘤细胞摄取~(86)Rb的光动力效应比两种药物单独应用的抑制作用大。 相似文献
108.
仇婷凤 《中国感染控制杂志》2003,2(3):193-194
目的 了解留置导尿所致尿路感染的发病率及影响因素。方法 采用前瞻性调查与回顾性调查相结合的方法,对妇产科手术后患者留置尿管而引发泌尿系感染率增高的原因进行调查和分析。结果 使用镇痛泵患者留置导尿后尿路感染率为5.45%,未用镇痛泵者的尿路感染率为0.21%,两者之间差异有高度显著性(P<0.005)。结论 镇痛泵不能滥用,使用时要避免诱发感染的因素。 相似文献
109.
The non-sulfhydryl selective angiotensin-converting enzyme inhibitor benazepril (20 mg daily) was compared with hydrochlorothiazide (50 mg daily) in post-infarction (6-24 months) patients with symptomatic (NYHA functional class 2) mild heart failure. No concomitant drug therapy was given. The study had a double-blind cross-over design with 3-month treatment periods. Both drugs were well tolerated, and both caused a similar reduction in systolic blood pressure. Heart rate was higher with the diuretic. Benazepril improved the NYHA functional class in 17 out of 29 (59%) patients, whereas one patient improved with hydrochlorothiazide (P = 0.0004). With regard to global efficacy score, benazepril was also superior. Thus, angiotensin-converting enzyme inhibitors may be superior to diuretics as first-choice therapy in symptomatic mild heart failure. 相似文献
110.
F. A. MacNeill S. Jacobs M. Dowsett P. E. Lonning T. J. Powles 《Cancer chemotherapy and pharmacology》1995,36(3):249-254
This study investigated the influence of the aromatase inhibitor 4-hydroxyandrostenedione (4OHA, formestane), given orally, on peripheral aromatase activity and plasma oestradiol (E
2) levels in post-menopausal women with advanced breast cancer. The aim was to establish whether an optimal dose could be identified that had a pharmacological effectiveness comparable with that of parenteral 4OHA. A total of 13 post-menopausal women were studied before treatment and after a minimum of 4 weeks on treatment with one or more of the following doses: 125 mg once daily (od), 125 mg b.i.d. (bd) and 250 mg od. In all, seven aromatase studied were performed at 125 mg od; four, at 125 mg bd; and ten, at 250 mg od. Three patients were studied at all doses. E2 was measured concurrently and was available at all dose increments for seven patients. Given at doses of 125 mg od, 125 mg bd and 250 mg od, treatment with formestane inhibited in vivo aromatisation by 62.3%±9.5%, 70.0%±5.1% and 57.3%±5.3%, respectively (mean±SEM). Corresponding values for plasma E2 suppression were 30.7%±6.5%, 43.4%±4.5% and 42.9%±6.7%, respectively. Thus, apart from a somewhat better suppression of plasma E2 levels by the two higher doses as compared with 125 mg od, no significant difference in the degree of aromatase inhibition or plasma E2 suppression was observed. The suppression of E2 by oral 4OHA at 125 mg bd or 250 mg od approaches that achieved by the recommended parenteral schedule of 250 mg fortnightly, but inhibition of aromatase at this dose was substantially inferior. The findings are consistent with a hypothesis that 4OHA given orally may cause substantial plasma oestrogen suppression during part of the day, but neither the od nor the bd regimens investigated in the present study were capable of producing optimal aromatase inhibition. 相似文献